GlassScriptPhysician profile
Melissa Headrick
NPI 1568600062
$5,788.24
in general payments reported to CMS, 2019-2025
25 companies · $639 in 2025
The $639 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $640 · 2022: $1,336 · 2023: $1,778 · 2024: $1,395 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,803 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,803.40 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,105.49 | 2021-2025 | |
| Abbvie INC. | $967.31 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $578.74 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Regeneron Healthcare Solutions, INC. | $382.40 | 2022-2025 | Dupixent |
| Pfizer INC. | $382.26 | 2021-2024 | |
| Lilly USA, LLC | $324.47 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $277.02 | 2021-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $269.60 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $263.45 | 2021-2024 | |
| Incyte Corporation | $195.41 | 2021-2025 | Opzelura |
| Amgen INC. | $192.16 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $170.59 | 2022-2024 | Vtama |
| Leo Pharma INC. | $124.46 | 2021-2025 | Anzupgo, Adbry |
| Almirall LLC | $106.27 | 2021-2023 | Seysara |
| Arcutis Biotherapeutics, INC. | $92.98 | 2023-2024 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $83.51 | 2021-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $77.66 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.80 | 2022-2024 | Siliq, Duobrii, Targretin |
| Galderma Laboratories, L.P. | $31.47 | 2024-2025 | Nemluvio |
| Organon LLC | $26.24 | 2023-2025 | Hadlima, Vtama |
| Verrica Pharmaceuticals INC. | $24.23 | 2024 | Ycanth |
| Biofrontera INC. | $17.23 | 2024 | Ameluz, Rhodoled Xl, Xepi |
| Botanix Sb INC | $15.20 | 2025 | Sofdra |
| Boston Scientific Corporation | $13.75 | 2024 | Rezum Generator |
| Kyowa Kirin, INC. | $13.54 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Headrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.